Dr. Robin Downing podcast highlights practical OA pain management

CURRENT FULL VERSION: Clinician’s Brief used its latest podcast with Dr. Robin Downing to revisit one of companion animal medicine’s most common chronic-pain problems: osteoarthritis, and what veterinarians can do about it in real practice. The episode, sponsored by PRN Pharmacal, positions Downing as a guide to practical pain and inflammation management, with an emphasis on implementing “complete and effective strategies” and helping pet parents recognize pain earlier. A related Clinician’s Brief partner podcast broadened that same conversation from pain control into mobility and joint health more generally: sports medicine and rehab specialist Dr. Matt Brunke argued that management needs to go beyond medications and supplements alone, especially when clinicians are trying to preserve function and quality of life over time. (cliniciansbrief.com)

That framing fits the broader arc of OA care over the past several years. The 2022 AAHA Pain Management Guidelines for Dogs and Cats emphasized that chronic musculoskeletal pain should be treated with a tiered, multimodal plan rather than a single intervention, pairing pharmaceuticals with weight control, exercise, rehabilitation, environmental modification, and other nonpharmacologic tools. AAHA’s senior care resources have reinforced the same point, especially for aging patients whose pain, mobility loss, sarcopenia, and comorbid disease often overlap. Brunke’s discussion adds a useful clinical reminder here: cats are easy to underprioritize in mobility conversations, even though obesity and longer lifespans mean many develop primary OA and show it through reduced jumping, altered activity, or other subtle functional changes rather than obvious lameness. (aaha.org)

What’s changed is the treatment landscape around that framework. FDA approved Librela, the first monoclonal antibody for canine OA pain, in May 2023, giving practices a once-monthly anti-NGF option for dogs. In February 2025, the drug’s U.S. labeling was updated with additional safety information, and the FDA’s safety-labeling page notes that it may take two monthly injections before a reduction in pain is seen. Meanwhile, Zoetis announced results from a 2025 clinical trial comparing bedinvetmab with meloxicam, saying the study found equivalent pain relief between the two approaches. (fda.gov)

Those developments help explain why a “practical advice” conversation matters now. For many clinicians, OA appointments increasingly involve choosing among NSAIDs, anti-NGF biologics, adjunctive analgesics, rehab plans, joint diets, and body-condition interventions, then revisiting those decisions over time. The evidence base still supports multimodal care as the standard frame, and even sources discussing newer biologics describe successful OA management as dependent on regular reassessment rather than one-and-done prescribing. Brunke’s mobility-focused comments also underscore that clinicians are often managing more than arthritis alone: ligament injury recovery, deconditioning, obesity, and home-activity limitations can all shape how a patient moves and how owners perceive improvement. (aaha.org)

Industry and expert reaction has been mixed, which is itself part of the story. Zoetis has highlighted head-to-head data supporting Librela alongside guideline recommendations that place both NSAIDs and Librela among first-line options for canine OA pain. At the same time, a 2025 Frontiers commentary reported a disproportionality analysis suggesting elevated reporting of serious musculoskeletal adverse events in dogs receiving bedinvetmab compared with several other OA medications, aligning that concern with earlier FDA pharmacovigilance attention. That commentary does not establish causation, but it adds to the pressure on clinics to document baseline disease, discuss uncertainty clearly, and monitor patients closely after treatment changes. (news.zoetis.com)

Why it matters: For veterinary teams, the Downing discussion is less about a new product launch than about clinical discipline. OA pain is common, progressive, and often underrecognized by pet parents, so practices that build structured pain assessments, mobility histories, weight-management plans, and follow-up checkpoints are better positioned to improve quality of life. The business and workflow implications are real, too: monthly injectables may improve adherence for some families, while NSAIDs may remain preferable for others, especially when cost, response, access, or clinician comfort drive the decision. Brunke’s emphasis on mobility as a day-to-day quality-of-life issue also supports a broader exam-room approach—asking not just whether a pet hurts, but whether it can rise, jump, navigate the home, exercise safely, and maintain conditioning. Either way, the standard of care is moving toward more deliberate multimodal planning and better communication, not narrower therapy selection. (cliniciansbrief.com)

What to watch: The next phase in OA management will likely center on how frontline clinicians integrate newer anti-NGF data with long-standing NSAID use, and whether additional safety analyses, label changes, or comparative studies further refine patient selection. Expect continued attention to monitoring protocols, pet parent informed-consent conversations, and the role of rehab, nutrition, weight control, and home-environment support as the foundations that make any pharmacologic plan work better. (fda.gov)